A great two days at ‘Safety of Stem Cell-Derived Therapies: Trends in Future Technologies’ in Edinburgh that Sistemic attended on October 7-8 2019
News
Sistemic will be attending Safety of Stem Cell-Derived Therapies: Trends in Future Technologies, Edinburgh, on October 7-8 2019
Come and meet Sistemic at Stand 4 to learn about our first-in-class miRNA assay SistemPSCCheckTM for detection of residual PSCs in derived cell therapies.
We would love to talk to you about how we can support you in the development of your stem cell therapy products
Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products by the granting of “Cell Characterisation” European patent No. EP2609217
Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products by the granting of “Cell Characterisation” European patent No. EP2609217
The European Patent Office communicated its decision to grant European Patent No. EP2609217, in the name of Sistemic Scotland Ltd titled “Cell Characterisation”.
The patent covers the use of microRNA profiles for quality assessment of stem cells and derived cell therapy products.
